Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Cetuximab Misses ORR End Point in RAS Wild-Type, BRAF V600E+ mCRC

June 7th 2021

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.

Lenvatinib Plus Pembrolizumab May Increase OS Rates in Advanced Colorectal Cancer

June 4th 2021

Some patients with previously treated advanced colorectal cancer responded to treatment with lenvatinib plus pembrolizumab.

Dr. Choti on Pursuing Chemotherapy Following Tumor Resection in Advanced CRC

June 1st 2021

Michael A. Choti, MD, discusses pursuing chemotherapy following tumor resection in advanced colorectal cancer.

Selecting Systemic Therapy for Newly Diagnosed mCRC

June 1st 2021

Treatment approaches available for patients with newly diagnosed metastatic colorectal cancer that is RAS wild type and factors that impact decisions for utilizing a 2-drug versus 3-drug regimen.

Next-Generation Sequencing in Metastatic Colorectal Cancer

June 1st 2021

Drs Jaffer A. Ajani and Zev A. Wainberg comment on the rationale for conducting full next-generation sequencing panels on patients with metastatic colorectal cancer and explain how to best utilize information provided to inform treatment decisions.

Prevalence of Precancerous CRC Lesions Warrants Screening in Younger Population

May 29th 2021

A significant incidence of advanced neoplasia and colorectal cancer was identified in individuals between the ages of 45 and 49 years, emphasizing the importance of adhering to recent recommendations from the United Services Preventive Services Task Force to lower the CRC screening age from 50 to 45 years.

Exciting Treatment Opportunities in mCRC

May 28th 2021

Closing out a discussion on novel therapies used to individualize treatment for patients with metastatic colorectal cancer, a panel of gastrointestinal oncologists highlight the most exciting treatment opportunities being explored to address current gaps in care.

Decisions for Sequencing Therapy for HER2-Expressing mCRC

May 28th 2021

Considerations regarding best sequencing strategies with novel therapies to treat HER2-mutated metastatic colorectal cancer.

Novel Therapies for HER2-Expressing mCRC

May 28th 2021

Implications for treating patients with HER2-expressing metastatic colorectal cancer with novel agents such as trastuzumab deruxtecan and tucatinib.

ctDNA Could Become the Next Pillar of Treatment Selection in mCRC

May 27th 2021

Kanwal Raghav, MBBS, MD, discusses current sequencing approaches in metastatic colorectal cancer.

Routine Screening Rates for Breast, Colorectal, and Prostate Cancers Decline During COVID-19 Pandemic

May 25th 2021

Screenings for breast cancer, colorectal cancer, and prostate cancer declined sharply from March to May 2020 vs the same time span in 2019, suggesting that public health efforts, such as increased use of screening modalities that do not require a procedure, are needed to address the deficit caused by the COVID-19 pandemic.

Molecular Testing in Metastatic Colorectal Cancer

May 25th 2021

The significance of studying genomics in metastatic colorectal cancer and an overview of actionable targets that can be tested for to help in treatment decisions for newly diagnosed disease.

Trends in Colorectal Cancer Incidence

May 25th 2021

Dr Jaffer A. Ajani highlights the increasing incidence of colorectal cancer diagnoses in younger patients as a growing concern during a discussion on trends in prevalence.

Nivolumab/Ipilimumab Approaches EU Approval for Post-Chemo dMMR or MSI-H Metastatic CRC

May 24th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the combination of nivolumab and ipilimumab as an option for patients with mismatch repair deficient or microsatellite instability–high metastatic colorectal cancer following fluoropyrimidine-based combination therapy.

Research Efforts Examining Novel Radiation Approaches Flourish at Fox Chase Cancer Center

May 21st 2021

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Novel Combinations Being Investigated for mCRC Treatment

May 21st 2021

Current trials exploring novel combinations that show potential in making microsatellite stable tumors hot and amenable to response to immunotherapy in metastatic colon cancer.

Dual I-O Therapy for mCRC

May 21st 2021

Drs Cathy Eng and Joleen M. Hubbard discuss the rationale for studying dual immunotherapy approaches for metastatic colorectal cancer treatment.

Dr. Eng on the Rationale for Studying the Impact of RAS Mutations in Early Onset Resectable CRC

May 21st 2021

Cathy Eng, MD, FACP, FASCO, discusses the rationale for studying the impact of RAS mutations in patients with early onset resectable colorectal cancer.

Dr. Eng on Surgical Considerations for RAS-Mutant CRC

May 19th 2021

Cathy Eng, MD, FACP, FASCO, discusses surgical considerations for patients with RAS-mutant colorectal cancer.

Dr. Hubbard on Utilizing Single-Agent Immunotherapy in MSI-H CRC

May 18th 2021

Joleen M. Hubbard, MD, discusses the potential for treatment with immunotherapy alone in patients with colorectal cancer.